Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study
There were no new safety signals for AEs of hepatic function disorder, and the incidence was consistent with that reported in KEYNOTE-426, in Japanese patients with radically unresectable/metastatic RCC treated with pembrolizumab plus axitinib.
Authors
- Masahiro Hamada
- Takuto Tokudome
- Shinichiroh Maekawa
- Yuichiro Ito
- Shotaro Yasuoka (ORCID: https://orcid.org/0000-0001-5749-0993)
- Masahiko Ozaki
- Mototsugu Oya (ORCID: https://orcid.org/0000-0002-2048-4263)
- Toshihiko Minegishi
Institutions
- Keio University (JP)
- MSD K.K. (Japan) (JP)
Publication Details
- Journal
- International Journal of Clinical Oncology
- Published
- 2025-04-29
- DOI
- https://doi.org/10.1007/s10147-025-02708-2
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- MSD K.K.